Cancer Care Ontario | Cancer Care Ontario

olaparib - For the maintenance treatment of BRCA-mutated, high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients, based on criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

olaparib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Dec 2024

Guidelines and Advice

Guidelines on Management of Nausea and Vomiting and on Loss of Appetite, Anorexia, and Cachexia in Cancer

Status: Current
ID: ES SMG-2

Jun 2018

Guidelines and Advice

The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement

Status: Current
ID: GL END 2-31

Jul 2018

Guidelines and Advice

Safety Considerations for the Implementation of Subcutaneous Rituximab Formulation

Status: Current
Version: 1

Jun 2018

NIVL

Immune Checkpoint Inhibitor Toxicity Management Clinical Practice Guideline

Systemic therapy for the treatment of adult patients with lower-risk myelodysplastic syndromes

Recommendations for the Delivery of Psychosocial Oncology Services in Ontario

Molecular Analyses in the Diagnosis, Prognosis, and Selection of Therapy in non-GIST Soft Tissue Sarcomas

PET Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2017

CHOP

Gastroscopy Standards and Quality Indicators for Ontario

OLAP

Guidelines on Management of Nausea and Vomiting and on Loss of Appetite, Anorexia, and Cachexia in Cancer

The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement

Safety Considerations for the Implementation of Subcutaneous Rituximab Formulation

Pages